Cetuximab (Erbitux) Pharmacokinetic ELISA
1223.35 €
In Stock
quantity
product details
Catalog number: 1061 - EL-1611-031
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 1X96 wells
EL-1611-031
Cetuximab (Erbitux) Pharmacokinetic ELISA
Cetuximab (Erbitux®) is a chimeric IgG1 monoclonal antibody that binds the extra-cellular domain of the epidermal growth factor receptor (EGFR). It is a 152-kDa molecule composed of four polypeptide chains: two identical heavy chains and two identical light chains, consisting of 449 and 214 amino acids, respectively, bound by covalent and non-covalent bonds. The bond with EGFR is characterized by a higher affinity than either endogenous ligand, as epidermal growth factor (EGF), or transforming growth factor alpha. This binding inhibits activation of the receptor tyrosine kinase and the associated downstream signaling that includes the mitogenactivated protein kinase, phosphoinositide 3-kinase/ Akt and the Janus kinases/ signal transducers and activator of transcription (Stat) pathways. Furthermore Cetuximab induces antibody-mediated receptor dimerization, internalization and degradation leading to receptor down-regulation. In addition, it exhibits antibody-dependent cellular cytotoxicity that could contribute to its antitumor effect. The Cetuximab ELISA kit is designed to measure free Cetuximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Cetuximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Cetuximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Cetuximab present in test samples and the concentration is calculated from the standard series.
1223.35 €
EL-1611-011
Adalimumab (Humira) Pharmacokinetic ELISA
Adalimumab (Trade name Humira®) is a human monoclonal antibody used to block the action of tumor necrosis factor alpha (TNF- ). TNF-α is a strong proinflammatory cytokine involved in normal immunity and also various autoimmune diseases. The Adalimumab ELISA kit is designed to measure free Adalimumab with high specificity and sensitivity. The assay design uses a pair of antibodies allowing detection of whole Adalimumab molecules in biological matrices The Adalimumab ELISA kit is designed to measure free Adalimumab with high specificity and sensitivity. This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Adalimumab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Adalimumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Adaliumumab present in test samples and the concentration is calculated from the standard series.
1223.35 €